Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: A review of the Japanese literature by Izumikawa Koichi et al.
Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae 
pneumonia: A review of the Japanese literature 
 
1, 2Koichi Izumikawa, 3Kinichi Izumikawa, 1Takahiro Takazono, 2Kosuke Kosai, 
4Yoshitomo Morinaga, 1Shigeki Nakamura, 1,2Shintaro Kurihara, 1Yoshifumi Imamura, 
1Taiga Miyazaki, 2Misuzu Tsukamoto, 4Katsunori Yanagihara, 2Kohei Hara and 1Shigeru 
Kohno 
 
1Department of Molecular Microbiology and Immunology, Nagasaki University 
Graduate School of Biomedical Sciences, Nagasaki, Japan 
2Nagasaki University Infection Control and Education Center, Nagasaki University 
Hospitals, Nagasaki, Japan 
3Department of Internal Medicine, Izumikawa Hospitals, Nagasaki, Japan  
4Department of Laboratory Medicine, Nagasaki University Hospitals, Nagasaki, Japan 
 
Corresponding author: 
Koichi IZUMIKAWA, M.D., Ph.D. 
Department of Molecular Microbiology and Immunology, 
1 
 
Nagasaki University Graduate School of Biomedical Sciences 
1-7-1 Sakamoto, Nagasaki 852-8501, Japan 









Mycoplasma pneumoniae (MP) is one of the most common causes of 
community-acquired pneumonia in children and young adults. Although MP sometimes 
causes self-limiting pneumonia, severe and fulminant cases with hypoxia occur, but 
their clinical features have rarely been reported. This study aimed to reveal the clinical 
manifestations, risk factors, and treatment of fulminant MP pneumonia (MPP). Using 
PubMed and abstracts from the proceedings of several domestic Japanese academic 
societies, we reviewed the Japanese and English literature for cases of fulminant or 
severe MPP reported in Japan. All clinical information such as sex, age, underlying 
diseases, clinical symptoms, clinical course, laboratory and radiological findings, and 
treatment was collected and analyzed. In total, 52 fulminant MPP cases were reported 
between September, 1979 and February, 2010. The dominant population of fulminant 
MPP was young adults without severe underlying diseases. Cough (97.3%), fever 
(100.0%), and dyspnea (83.3%) with diffuse abnormal findings in radiological 
examinations were noted. Antibiotics without anti-mycoplasmal activity were used in 32 
cases (61.5%) as initial treatment prior to the onset of hypoxia. Anti-mycoplasmal drugs 
were appropriately used in 41 cases (78.8%) after onset of respiratory failure with 
steroids (23 cases, 45.1%) and effective. The majority of patients improved within 3–5 
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days after steroid administration. There were only 2 fatal cases. Although this small 
retrospective study did not reveal the apparent risk factors of fulminant MPP, initial 
inappropriate use of antibiotics may be a risk factor, and early administration of 






Mycoplasma pneumoniae is one of the most common causes of atypical pneumonia 
worldwide occurring in all populations especially youths. Transmission of M. 
pneumoniae occurs via infected respiratory droplets during close contact between the 
source and the recipient. Atypical pneumonia is considered to account for 7-20% of 
community-acquired pneumonia (CAP) [1,2]. Previous Japanese epidemiological 
studies of CAP have also indicated a prevalence of 5.2-15.4%, which does not differ 
from the data of studies carried out in other countries [3-5]. The actual incidence of M. 
pneumoniae pneumonia (MPP), however, may be higher in patients with mild 
symptoms that can be managed without hospital admission. Commonly, patients with 
mycoplasma respiratory infection may have nonproductive, persistent cough, 
pharyngitis, rhinorrhea, and occasional extrapulmonary manifestations such as 
hemolysis, skin reactions (e.g.. the Stevens-Johnson syndrome), and central nervous 
system complications. Although MPP is sometimes self-limiting, and macrolides are 
effective against it, numerous fulminant cases of MPP, including that of acute 
respiratory distress syndrome (ARDS), have been reported to date [6,7]. The major 
clinical manifestation of fulminant MPP is respiratory failure with diffuse consolidation 
or an abnormal interstitial pattern that can be observed on a chest radiograph. The 
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incidence of fulminant MPP is relatively rare despite the high prevalence of M. 
pneumoniae infection, and its etiology has not been fully described. The clinical 
features of fulminant MPP have not been clearly elucidated either. 
We reviewed 52 cases of fulminant MPP with respiratory failure; we obtained their 
reports from multiple institutes and clinics in Japan and analyzed their clinical 
characteristics, risk factors, and treatment.  
 
MATERIAL & METHODS 
Case collection 
  Using PubMed and abstracts from the proceedings of several domestic Japanese 
academic societies, we searched the Japanese and English literature for cases of 
fulminant or severe MPP reported in Japan before February, 2010. Fulminant MPP was 
defined as the apparent presence of MP infection with hypoxia. All cases must ful1filled 
following conditions; (1) the patients should be diagnosed with MPP after obtaining 
positive findings from any of microbiological laboratory tests such as culturing or 
serological antibody tests including the passive agglutination (PA) test, complement 
fixation (CF) test, or indirect hemagglutinin (IHA) test in either single titer (titers of ≥
64, ≥320 and ≥320 were considered positive for CF and IHA, and PA, respectively) or 
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elevated paired titer (a 4-fold increase in paired serum was considered positive), 
immunochromatography (IgM), or PCR; and (2) the patient should present no evidence 
of causative agents other than MP; and (3) the patient should have experienced acute 
onset of hypoxia with no previous history of respiratory failure (PaO2 < 80.0 torr or 
arterial oxygen saturation < 95.0% at room air). All information in the acquired 
literature, such as sex, age, underlying diseases, clinical symptoms, clinical course, 
laboratory and radiological findings, and treatment, was collected and analyzed. We 




Correlation of the radiological findings and severity of inflammation using 
inflammation markers such as white blood cell (WBC) count, C-reactive protein (CRP) 
level, and erythrocyte sedimentation rate (ESR) were analyzed by Kruskal-Wallis test. 
Risk factor of mechanical ventilation was evaluated in the multivariate analysis. Values 
of p <0.05 were considered statistically significant. The statistical analysis was made 
using the SPSS V20 FOR WINDOWS (SPSS Inc., Chicago, IL, USA) and PRISM 





  We found and analyzed 52 cases in the literature between September, 1979 and 
February, 2010. All cases involved Japanese patients and MP infection was diagnosed 
by serological antibody tests such as PA, CF, and IHA. PA, CF, and IHA diagnosed 15, 
27, and 20 cases, respectively, and confirmed single titer elevation in 2, 3, and 4 cases, 
respectively. The remaining cases were diagnosed by paired titer elevation in serum 
samples. MP was isolated in 2 of 3 cases in which culture was attempted. No case 
diagnosed by PCR or IgM immunochromatography was confirmed. The incidence of 
MPP was predominant among men (29 cases). Almost 50% of fulminant MPP cases 
(44.2%) occurred in patients aged 20–49 years (mean age, 42.3 years). Fourteen cases 
(26.9%) were reported among patients aged 30–39 years. There were 7 cases (13.5%) of 
fulminant MPP in the elderly (age > 70 years). Four cases were found among younger 
patients (age <20 years). Table 1 indicates the patients’ underlying diseases. The 
majority of fulminant MPP patients (72.5%) had no underlying diseases, and 14 patients 
were current smokers.  
The average PaO2 of all patients was 52.3 torr, and 16 cases (30.1%) had severe 
hypoxia, with PaO2 <50 torr. Mechanical ventilation was carried out in 15 patients 
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(28.8%). An extremely high PaCO2 (>100 torr) was observed in 3 cases, chronic 
bronchitis was the underlying disease in 2 cases, and 1 case had no underlying disease. 
The reason for the patients’ high PaCO2 was unclear. 
 
Clinical features of fulminant MPP 
 All patients (100%) presented with fever (>37.0°C) at their first visit to the hospital. 
The distribution of fever is shown in Table 2. A relatively high fever (>38.0°C) was 
observed in 46 cases (88.5%). Respiratory symptoms such as cough and dyspnea were 
observed on admission in 51 (97.3%) and 43 (83.3%) cases, respectively. The frequency 
of other upper respiratory symptoms and sputum production was lower (26.9% had 
sputum production). The average WBC count, CRP level, and ESR on admission were 
10,486/μL (51 cases), 19.1 mg/dL (41 cases), and 70.4 mm/h (41 cases), respectively. 
The majority of severe MPP cases exhibited a relatively moderate inflammation 
response. Elevated serum aspartate amino transferase (AST) and alanine transaminase 
(ALT) levels (>40 IU) at the onset of respiratory failure was observed in 28 (60.9%) of 
46 cases. All abnormal findings disappeared within 7–10 days of the onset of respiratory 
failure. The average serum total protein and albumin were 6.4 g/dL and 3.0 g/dL, 
respectively, among 34 cases; 11 cases (32.3%) exhibited low serum protein and 
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albumin levels. Sputum culture was performed for 35 cases, and normal flora were 
detected in 33 cases (94.3%). Klebsiella pneumoniae was detected in 2 cases but not 
considered a causative agent together with MP. The tuberculin reaction test was 
performed in 34 cases, and 32 cases (94.1%) produced a negative reaction. The average 
duration from onset of infection to the development of respiratory failure was 11.2 days 
in 51 cases (range, 5–21 days). 
 
Radiological features of fulminant MPP 
  Analysis of chest radiography findings, including computed tomography scans, was 
performed in all 52 cases. A diffuse interstitial pattern (e.g., reticular, nodular, linear) 
was observed in 32 cases (61.5%). A diffuse alveolar pattern with or without air 
bronchogram was observed in 13 cases (25.0%). A mixed interstitial and alveolar 
pattern was observed in 7 cases (13.5%). Pleural effusion was noted in 7 cases, and 
these cases were categorized as either alveolar or mixed pattern cases. Correlation of the 
radiological findings and severity of inflammation using inflammation markers 
indicated that mixed pattern cases had higher CRP (n = 5, 28.7 mg/dL) compared to that 
of interstitial (n = 26, 17.2 mg/dL) or alveolar pattern (n = 10, 19.1 mg/dL) cases, 
however, there was no statistical different (p = 0.143). No such trend was identified 
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when comparing the findings of WBC counts and ESR, either. 
 
Pathological features of fulminant MPP 
  Pathological investigation was performed in 24 cases: transbronchial lung biopsy (20 
cases), open lung biopsy (3 cases), and autopsy (1 case). Table 3 lists the pathological 
findings and the average duration (days) from onset of infection to the pathological 
examinations being performed. Acute bronchiolitis was identified in the early phase of 
infection, followed by organizing pneumonia and alveolitis with or without granuloma 
formation at the recovery phase. These findings, however, were acquired from different 
cases. Diffuse alveolar damage was reported in 1 of the fatal cases.  
 
Treatment of fulminant MPP 
  The initial treatment prior to respiratory failure is summarized in Table 4. Appropriate 
anti-mycoplasmal drugs such as macrolides (erythromycin, clarithromycin, and 
azithromycin) were used as primary treatment for MPP in only 6 of 52 cases. 
Beta-lactams and aminoglycosides, which have no potent activity against MP infection, 
were used as initial treatment in 32 cases (61.5%). The total rate of both inappropriate 
treatment and no-treatment cases was 78.8% (41 cases). No patients were treated with 
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quinolones or tetracyclines. The treatment after onset of respiratory failure is 
summarized in Table 5. Anti-mycoplasmal drugs with steroids were used in 23 cases 
(45.1%), and minocycline was used in almost half of these cases. Single administration 
of anti-mycoplasmal drugs without steroids were used in 18 cases (35.2%). No patients 
were administered antimicrobial agents without anti-mycoplasmal activity.  
The efficacy of the steroids was assessed; Table 6 summarizes the dose, duration, and 
efficacy of steroids for fulminant MPP. Methylprednisolone was administered at over 
500 mg/day to almost half of the patients, and the majority of these patients showed 
improvement within 3–5 days of steroid treatment. Prednisolone dosage was gradually 
tapered within a week for almost all cases. There were 4 patients who remained 
unresponsive after a week of steroid treatment; however, all patients showed 
improvement in 14 days. 
 
Outcome of fulminant MPP 
 Only 2 deaths were reported among the 52 reviewed cases; the remaining 50 patients 
recovered. Fulminant MPP occurred in a 64-year-old apparently healthy woman who 
died from multiple organ failure although she was administered with a combination of 
erythromycin and steroids 2 days after admission. The patient received her first dose of 
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anti-mycoplasmal drugs only 17 days after the first appearance of respiratory 
symptoms; only beta-lactams were used before admission [8]. In another case, an 
18-year-old man died due to Stevens-Johnson syndrome, which occurred as a 
complication of MP infection. The autopsy revealed apparent diffuse alveolar damage. 
Minocycline was administered only 7 days after the onset of MP infection. Although 
steroid therapy was initiated on day 4, the patient’s condition did not improve. 
 
DISCUSSION 
The incidence of respiratory failure in cases of fulminant MPP has rarely been reported 
despite the high prevalence of MPP [6]. Among 295 MPP cases, we have encountered 
only 3 patients (1.0%), which presented respiratory failure (data not published).  
MPP is sometimes a self-limiting disease; however, the following are considered 
virulence-associated factors of MP: 1) direct interaction between human host cells 
caused by toxicity (e.g., adherence to bronchoepithelial cells, toxin production, reactive 
oxygen species, and cytokines), and 2) indirect interaction of immunological or allergic 
reaction to MP infection [9,10]. Although the apparent mechanism and etiology of 
fulminant MPP have not been revealed, there are at least 3 possible hypotheses: 1) 
hyperimmune response originating in the lung due to repeated childhood MP infections, 
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2) loss of the ability to eradicate MP from the lung in primary infection resulting in 
longer-lasting MP infection in the lung, which may cause a hyperimmune response, and 
3) overactive innate immune response such as macrophage activation via 
heterodimerization of Toll-like receptors 2 and 6 of the bronchoepithelial cells to MP 
lipoproteins [11]. Thus, the immunological hyper-reaction in the lung may induce 
lymphocyte activation, resulting in systemic impairment of cellular immunity and 
progression to fulminant status.  
In this literature review, the majority of patients with fulminant MPP did not have 
underlying diseases, and very few patients were malnutritioned or had a history of 
smoking. Although the dominant population of fulminant MPP cases was young and 
healthy adults, MPP may become severe in elderly patients (age >70 years) (13%). All 
cases were confirmed as MPP infection with serological tests, the gold standard for 
diagnosis of MP infections. Although all cases were reported as M. pneumoniae single 
infection, it is possible that respiratory pathogens other than M. pneumoniae may have 
been involved. Since this was not a prospective study, the diagnostic methods for 
causative agents of pneumonia other than M. pneumoniae, such as culturing, serological 
tests, antigen detection, and PCR varied with each report. 
The clinical manifestations of fulminant MPP were cough, high fever, and hypoxia 
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with diffuse abnormal findings on radiologic examination. Varied chest radiographic 
patterns were recognized in patients with fulminant MPP, and these findings may reflect 
the difference in the immunological response (e.g., difference in cytokine production)  
[10]. Liver dysfunction such as ALT and AST elevation were common in fulminant MPP. 
This may not have been caused by the direct invasion of MP to liver tissue, and an 
indirect immunological response to MP in liver tissue is considered to have played an 
important role. There were 15 cases required mechanical ventilation (37 cases not) in 
this review, we compared following factors such as sex, average age, existence of 
underlying diseases, appropriateness of initial treatment, and radiological patterns to 
estimate the risk factors for requirement of mechanical ventilation. No significant 
factors were associated for the requirement of mechanical ventilation (data not shown).   
Cellular immunity is considered important in the etiology of MP infection, as 
described above. Since the Bacille Calmette-Guérin vaccination is common and adopted 
for routine childhood immunization in Japan, we consider negative tuberculin test 
results to be indicative of cellular immunity impairment in the Japanese population. The 
tuberculin test was negative in 94.1% of all cases. Data in our analysis supported the 
premise that early-phase impairment of cellular immunity may be correlated to the 
etiology of fulminant MPP. 
15 
 
The pathological findings demonstrated that acute bronchiolitis followed by organizing 
pneumonia, alveolitis, and granuloma formation were observed sequentially. Although 
this transitional change was not proved in one patient with several sequential tissue 
biopsy, the transition of the pathological findings was well-matched compared to that in 
a previous report [6].  
The onset of respiratory failure was between 5 and 21 days (average, 11 days) from the 
appearance of symptoms; beta-lactams, but not tetracyclines or macrolides, were used 
as initial treatment prior to the development of respiratory failure in the majority of 
cases. Eighteen and 7 days, respectively, had elapsed until the first administration of 
anti-mycoplasmal drugs in the 2 fatal cases in this study. Other fatal MP cases have 
been published recently [12,13], and 14 days had elapsed until the first administration of 
anti-mycoplasmal drugs in 1 case. On the other hand, we found that anti-mycoplasmal 
drugs were used in only 6 cases; however, relatively lower doses and shorter durations 
were used (data not shown). Taken together, inappropriate initial treatment with 
beta-lactams or other drugs with no anti-mycoplasmal activity, and delayed 
administration of anti-mycoplasmal drugs may be an important factor in the etiology of 
fulminant MPP. 
Administration of anti-mycoplasmal drugs with steroids was selected in this study as a 
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major treatment option after onset of respiratory failure. The administration of steroids 
without anti-mycoplasmal drugs also led to the improvement of respiratory failure. 
These findings support that steroids suppress cellular immunity, and they should thus be 
considered reasonable for management of fulminant MPP involving hyperactivated 
cellular immunity. However, the effect of steroids may reduce the native immune 
response to MP and increase the duration for MP eradication from the body. Therefore, 
longer periods of steroid administration should be avoided. Although it is difficult to 
illustrate the optimal duration and dose of steroids from the result of this study or other 
studies, methylprednisolone 500-1000 mg/day for 3 to5 day administration may be 
essential for patients with fulminant MPP especially for those who require mechanical 
ventilation. Furthermore, methylprednisolone 125-250 mg/day for 3 to5 day 
administration or more than 20mg/day of prednisolone for 5 to 7 days administration 
may be considered for the MPP patients without respiratory failure but with persistent 
fever or cough, dyspnea, wheezes, or diffuse pneumonia. Needless to say, the 
administration of appropriate anti-mycoplasmal drugs is strongly required for both 
conditions. Prospective studies may be warranted to determine the appropriate duration 
and dose of steroid administration in fulminant MPP. 
To enable the early and appropriate usage of anti-mycoplasmal drugs, early and precise 
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detection of MP infection is essential to prevent deterioration. As presented in this study, 
definite diagnosis remains dependent on serological tests, which may require several 
weeks, and the culture of mycoplasma is not practical. Although current rapid 
diagnostic tools using PCR, which has high specificity and sensitivity, are available 
[14,15], they may not be applicable in every medical institute. Thus, the development of 
newer diagnostic tools is warranted.    
Fulminant MPP case was defined as the presence of MP pneumonia with hypoxia in 
this study, and an apparent definition has not been established yet due to scarcity. Since 
our study is a descriptive and retrospective literature review of data from multiple 
institutes using our own case definition, there is a potential ascertainment bias in the 
patient selection as the limitation of the study.  
In conclusion, our analysis of the literature on fulminant MPP cases indicates that 
initial inappropriate use of antibiotics may be a risk factor for fulminant MPP and that 
early administration of appropriate anti-mycoplasmal drugs with steroids as cellular 
immune suppressors is required. 
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Table 1. Underlying diseases of fulminant Mycoplasma pneumoniae pneumonia cases 
 underlying diseases number of case (%) 
  diabetes mellitus 1 (2.0) 
  bronchial asthma 5 (9.8) 
  chronic bronchitis 3 (5.9) 
  collagen diseases 1 (2.0) 
  hyperthyroidism 1 (2.0) 
  spincerebellar degeneration 1 (2.0) 
  pregnancy 1 (2.0) 
  hypertension 2 (3.9) 
  hypertrophic cardiomyopathy 1 (2.0) 
none 37 (72.5) 
20 
 




symptoms and signs number of case (%) 
fever (ºC) 52 (100.0) 
    < 37.0  1 (3.8) 
    37.0 ~ 37.9 6 (11.5) 
    38.0 ~ 38.9 24 (46.2) 
    39.0 ~ 39.9 16 (30.8) 
> 39.9 5 (9.6) 
dyspnea 43 (82.7) 
cough 51 (98.1) 
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average days from onset to 
pathological examination 
  acute bronchiolitis 6 9.8 
  organizing pneumonia 12 17.9 
  alveolitis 9 34.2 
  alveolitis with granuloma formation 4 27.5 
  diffuse alveolar damage 1 15.0 





Table 4. Summary of treatment prior to the presence of respiratory failure in fulminant 
Mycoplasma pneumoniae pneumonia cases (52 cases) 
treatment number of case (%) 









no antibiotics 9 (17.3) 





Table 5. Summary of treatment after the presence of respiratory failure in fulminant 
Mycoplasma pneumoniae pneumonia cases (51 cases) 
treatment number of case (%) 









antibiotics + steroids 23 (45.1) 
minocycline + steroid 
erythromycin + steroid 
clarithromycin + steroid 
azithromycin + steroid 















Table 6. Summary of efficacy of steroid in fulminant Mycoplasma pneumoniae pneumonia cases (18 cases) 





1 40 F alveolar mPSL 1000mg (5) 5 
2 26 F alveolar mPSL 1000mg (5) 5 
3 35 F mixed mPSL 125mg (7)→250 (3) 8 
4 49 M interstitial PSL 40mg (7) 5 
5 21 F alveolar mPSL 
1000mg (3)→PSL  
tapered 
3 
6 52 F interstitial mPSL 1000mg (3)→PSL tapered 3 
7 26 F mixed mPSL 1000mg (5) 4 
8 35 M mixed PSL 60mg (5) 5 
9 16 F alveolar PSL 20mg (7) 5 
10 37 M interstitial Hydrocortisone 1000mg (3) 8 
11 36 M interstitial mPSL 500mg (5)→PSL tapered 3 
12 24 M mixed mPSL 300mg (5) 3 
13 60 F interstitial PSL 60mg (4) 40mg (2) 8 
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14 60 F interstitial PSL 40mg (7) 14 
15 37 M interstitial PSL 40mg (7) 7 
16 64 F alveolar mPSL 500mg unknown 
17 37 M alveolar mPSL 1000mg (3)→PSL tapered 5 
18 38 F interstitial PSL 30mg→20mg 6 
 
M, male; F, female; mPSL, methylprednisolone; PSL, prednisolone 
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